Enforcement of anti-bribery and corruption regulations is heavily on the radar for U.S. and international regulators and prosecutors and no industry is immune. Global life sciences organizations, through their sheer size and complexity, are ubiquitous candidates for the investigatory lenses of government agencies.
Life sciences companies must be vigilant and proactive in ensuring that they have deployed a robust and comprehensive anti-bribery and corruption compliance program.
According to the Navigant experts, "When discussing FCPA risks in the Life Sciences industry it is important to note that the industry is especially susceptible to such risks due to the fact that many health systems outside the United States are regulated, operated, controlled and financed by foreign governments.”
Read our step by step guidance for developing a robust and successful program.